Details for Patent: 5,922,706
✉ Email this page to a colleague
| Title: | Morpholine and thiomorpholine tachykinin receptor antagonists |
| Abstract: | Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia. |
| Inventor(s): | Dorn; Conrad P. (Plainfield, NJ), Hale; Jeffrey J. (Westfield, NJ), Maccoss; Malcolm (Freehold, NJ), Mills; Sander G. (Woodbridge, NJ), Shah; Shrenik K. (Metuchen, NJ), Ladduwahetty; Tamara (Buckhurst Hill, GB) |
| Assignee: | Merck & Co., Inc. (Rahway, NJ) |
| Filing Date: | Nov 13, 1997 |
| Application Number: | 08/969,685 |
| Claims: | 1. A compound of the structural formula: ##STR19## or a pharmaceutically acceptable salt thereof, wherein: R.sup.1 is selected from the group consisting of: (1) hydrogen; (2) C.sub.1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, wherein halo is fluoro, chloro, bromo or iodo, (h) --NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are independently selected from: (i) hydrogen, (ii) C.sub.1-6 alkyl, (iii) hydroxy-C.sub.1-6 alkyl, and (iv) phenyl, (i) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (j) --NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (k) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (l) --COR.sup.9, wherein R.sup.9 is as defined above, (m) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; (n) heterocycle, wherein the heterocycle is selected from the group consisting of: (A) benzimidazolyl, (B) benzofuranyl, (C) benzothiophenyl, (D) benzoxazolyl, (E) furanyl, (F) imidazolyl, (G) indolyl, (H) isooxazolyl, (I) isothiazolyl, (J) oxadiazolyl, (K) oxazolyl, (L) pyrazinyl, (M) pyrazolyl, (N) pyridyl, (O) pyrimidyl, (P) pyrrolyl, (Q) quinolyl, (R) tetrazolyl, (S) thiadiazolyl, (T) thiazolyl, (U) thienyl, (V) triazolyl, (W) azetidinyl, (X) 1,4-dioxanyl, (Y) hexahydroazepinyl, (Z) piperazinyl, (AA) piperidinyl, (AB) pyrrolidinyl, (AC) tetrahydrofuranyl, and (AD) tetrahydrothienyl, and wherein the heterocycle is unsubstituted or substituted with one or more substituent(s) selected from: (i) C.sub.1-6 alkyl, unsubstituted or substituted with halo, --CF.sub.3, --OCH.sub.3, or phenyl, (ii) C.sub.1-6 alkoxy, (iii) oxo, (iv) hydroxy, (v) thioxo, (vi) --SR.sup.9, wherein R.sup.9 is as defined above, (vii) halo, (viii) cyano, (ix) phenyl, (x) trifluoromethyl, (xi) --(CH.sub.2).sub.m --NR.sup.9 R.sup.10, wherein m is 0, 1 or 2, and R.sup.9 and R.sup.10 are as defined above, (xii) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (xiii) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (xiv) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above, and (xv) --(CH.sub.2).sub.m --OR.sup.9, wherein m and R.sup.9 are as defined above; (3) C.sub.2-6 alkenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, (h) --CONR.sup.9 R.sup.10 wherein R.sup.9 and R.sup.10 are as defined above, (i) --COR.sup.9 wherein R.sup.9 is as defined above, (j) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above, (k) heterocycle, wherein the heterocycle is as defined above; (4) C.sub.2-6 alkynyl; (5) phenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) C.sub.1-6 alkoxy, (c) C.sub.1-6 alkyl, (d) C.sub.2-5 alkenyl, (e) halo, (f) --CN, (g) --NO.sub.2, (h) --CF.sub.3, (i) --(CH.sub.2).sub.m --NR.sup.9 R.sup.10, wherein m, R.sup.9 and R.sup.10 are as defined above, (j) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (k) --NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (l) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (m) --CO.sub.2 NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (n) --COR.sup.9, wherein R.sup.9 is as defined above; (o) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; R.sup.2 and R.sup.3 are independently selected from the group consisting of: (1) hydrogen, (2) C.sub.1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, (h) --NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (i) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (j) --NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (k) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (l) --COR.sup.9, wherein R.sup.9 is as defined above, and (m) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; (3) C.sub.2-6 alkenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, (h) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (i) --COR.sup.9 wherein R.sup.9 is as defined above, (j) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; (4) C.sub.2-6 alkynyl; (5) phenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) C.sub.1-6 alkoxy, (c) C.sub.1-6 alkyl, (d) C.sub.2-5 alkenyl, (e) halo, (f) --CN, (g) --NO.sub.2, (h) --CF.sub.3, (i) --(CH.sub.2).sub.m --NR.sup.9 R.sup.10, wherein m, R.sup.9 and R.sup.10 are as defined above, (j) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (k) --NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (l) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (m) --CO.sub.2 NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (n) --COR.sup.9, wherein R.sup.9 is as defined above; (o) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; R.sup.6, R.sup.7 and R.sup.8 are independently selected from the group consisting of: (1) hydrogen; (2) C.sub.1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, (h) --NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (i) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (j) --NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (k) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (l) --COR.sup.9, wherein R.sup.9 is as defined above, and (m) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; (3) C.sub.2-6 alkenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, (h) --CONR.sup.9 R.sup.10 wherein R.sup.9 and R.sup.10 are as defined above, (i) --COR.sup.9 wherein R.sup.9 is as defined above, (j) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; (4) C.sub.2-6 alkynyl; (5) phenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) C.sub.1-6 alkoxy, (c) C.sub.1-6 alkyl, (d) C.sub.2-5 alkenyl, (e) halo, (f) --CN, (g) --NO.sub.2, (h) --CF.sub.3, (i) --(CH.sub.2).sub.m --NR.sup.9 R.sup.10, wherein m, R.sup.9 and R.sup.10 are as defined above, (j) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (k) --NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (l) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (m) --CO.sub.2 NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (n) --COR.sup.9, wherein R.sup.9 is as defined above; (o) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; (6) halo, (7) --CN, (8) --CF.sub.3, (9) --NO.sub.2, (10) --SR.sup.14, wherein R.sup.14 is hydrogen or C.sub.1-5 alkyl, (11) --SOR.sup.14, wherein R.sup.14 is as defined above, (12) --SO.sub.2 R.sup.14, wherein R.sup.14 is as defined above, (13) NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (14) CONR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (15) NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (16) NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (17) hydroxy, (18) C.sub.1-6 alkoxy, (19) COR.sup.9, wherein R.sup.9 is as defined above, (20) CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above, (21) 2-pyridyl, (22) 3-pyridyl, (23) 4-pyridyl, (24) 5-tetrazolyl, (25) 2-oxazolyl, and (26) 2-thiazolyl; R.sup.11, R.sup.12 and R.sup.13 are independently selected from the definitions of R.sup.6, R.sup.7 and R.sup.8 ; X is selected from the group consisting of: (1) --O--, (2) --S--, (3) --SO--, and (4) --SO.sub.2 --; Y is selected from the group consisting of: (1) a single bond, (2) --O--, (3) --S--, (4) --CO--, (5) --CH.sub.2 --, (6) --CHR.sup.15 --, and (7) --CR.sup.15 R.sup.16 --, wherein R.sup.15 and R.sup.16 are independently selected from the group consisting of: (a) C.sub.1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from: (i) hydroxy, (ii) oxo, (iii) C.sub.1-6 alkoxy, (iv) phenyl-C.sub.1-3 alkoxy, (v) phenyl, (vi) --CN, (vii) halo, (viii) --NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (ix) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (x) --NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (xi) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (xii) --COR.sup.9, wherein R.sup.9 is as defined above, and (xiii) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; (b) phenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (i) hydroxy, (ii) C.sub.1-6 alkoxy, (iii) C.sub.1-6 alkyl, (iv) C.sub.2-5 alkenyl, (v) halo, (vi) --CN, (vii) --NO.sub.2, (viii) --CF.sub.3, (ix) --(CH.sub.2).sub.m --NR.sup.9 R.sup.10, wherein m, R.sup.9 and R.sup.10 are as defined above, (x) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (xi) --NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (xii) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (xiii) --CO.sub.2 NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (xiv) --COR.sup.9, wherein R.sup.9 is as defined above, and (xv) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; and Z is hydrogen. 2. The compound of claim 1 wherein: R.sup.1 is C.sub.1-6 alkyl, substituted with one or more of the substituents selected from: heterocycle, wherein the heterocycle is selected from the group consisting of: (A) benzimidazolyl, (B) imidazolyl, (C) isooxazolyl, (D) isothiazolyl, (E) oxadiazolyl, (F) pyrazinyl, (G) pyrazolyl, (H) pyridyl, (I) pyrrolyl, (J) tetrazolyl, (K) thiadiazolyl, (L) triazolyl, and (M) piperidinyl, and wherein the heterocycle is unsubstituted or substituted with one or more substituent(s) selected from: (i) C.sub.1-6 alkyl, unsubstituted or substituted with halo, --CF.sub.3, --OCH.sub.3, or phenyl, (ii) C.sub.1-6 alkoxy, (iii) oxo, (iv) thioxo, (v) cyano, (vi) --SCH.sub.3, (vii) phenyl, (viii) hydroxy, (ix) trifluoromethyl, and (x) --(CH.sub.2).sub.m --NR.sup.9 R.sup.10, wherein m is 0, 1 or 2, and wherein R.sup.9 and R.sup.10 are independently selected from: (I) hydrogen, (II) C.sub.1-6 alkyl, (III) hydroxy-C.sub.1-6 alkyl, and (IV) phenyl, (xi) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, and (xii) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above. 3. A method for antagonizing the effect of substance P at its receptor site or for the blockade of neurokinin-1 receptors in a mammal which comprises the administration to the mammal of the compound of claim 1 in an amount that is effective for antagonizing the effect of substance P at its receptor site in the mammal. 4. A method for antagonizing the effect of neurokinin A at its receptor site or for the blockade of neurokinin-2 receptors in a mammal which comprises the administration to the mammal of the compound of claim 1 in an amount that is effective for antagonizing the effect of neurokinin A at its receptor site in the mammal. 5. A method of treating or preventing pain or nociception attributable to or associated with migraine in a mammal in need thereof which comprises the administration to the mammal of an effective amount of the compound of claim 1. 6. The compound of claim 1 wherein R.sup.1 is selected from the group consisting of: ##STR20## 7. The compound of claim 1 wherein R.sup.1 is selected from the group consisting of: (1,2,4-triazolo)methyl; and (5-oxo-1H,4H-1,2,4-triazolo)methyl. 8. The compound of claim 1 wherein R.sup.1 is selected from the group consisting of: (1,3-imidazolo)methyl; and (2-oxo-1,3-imidazolo)methyl. 9. The compound of claim 1 of the structural formula: ##STR21## or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.6, R.sup.7, R.sup.8, R.sup.11, R.sup.12, R.sup.13, Y and Z are as defined in claim 1. 10. The compound of claim 1 of the structural formula II: ##STR22## or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.6, R.sup.7, R.sup.8, R.sup.11, R.sup.12, R.sup.13 and Z are as defined in claim 1. 11. The compound of claim 1 of the structural formula III: ##STR23## or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.6, R.sup.7, R.sup.8, R.sup.11, R.sup.12, R.sup.13 and Z are as defined in claim 1. 12. The compound of claim 1 of the structural formula: ##STR24## or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.6, R.sup.7, R.sup.8, R.sup.11, R.sup.12, R.sup.13, Y and Z are as defined in claim 1. 13. The compound of claim 1 of the structural formula: ##STR25## or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.6, R.sup.7, R.sup.8, R.sup.11, R.sup.12, R.sup.13, Y and Z are as defined in claim 1. 14. The compound of claim 1 of the structural formula: ##STR26## or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.6, R.sup.7, R.sup.8, R.sup.11, R.sup.12, R.sup.13, Y and Z are as defined in claim 1. 15. A method of treating a condition selected from the group consisting of: diabetic neuropathy; peripheral neuropathy; AIDS related neuropathy; chemotherapy-induced neuropathy; and neuralgia, in a mammal in need thereof which comprises the administration to the mammal of an effective amount of the compound of claim 1. 16. A method for the treatment or prevention of asthma in a mammal in need thereof which comprises the administration to the mammal of an effective amount of the compound of claim 1, either alone or in combination with a neurokinin-2 receptor antagonist or with a .beta..sub.2 -adrenergic receptor agonist. 17. A method for the treatment of cystic fibrosis in a mammal in need thereof which comprises the administration to the mammal of an effective amount of the compound of claim 1. 18. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of the compound of claim 1. 19. A method for the treatment or prevention of emesis in a mammal in need thereof which comprises the administration to the mammal of an effective amount of the compound of claim 1. 20. A process for the preparation of a compound of structural formula IV: ##STR27## or a pharmaceutically acceptable salt thereof, wherein: R.sup.1 is selected from the group consisting of: (1) hydrogen; (2) C.sub.1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, wherein halo is fluoro, chloro, bromo or iodo, (h) --NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are independently selected from: (i) hydrogen, (ii) C.sub.1-6 alkyl, (iii) hydroxy-C.sub.1-6 alkyl, and (iv) phenyl, (i) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (j) --NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (k) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (l) --COR.sup.9, wherein R.sup.9 is as defined above, (m) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; (n) heterocycle, wherein the heterocycle is selected from the group consisting of: (A) benzimidazolyl, (B) benzofuranyl, (C) benzothiophenyl, (D) benzoxazolyl, (E) furanyl, (F) imidazolyl, (G) indolyl, (H) isooxazolyl, (I) isothiazolyl, (J) oxadiazolyl, (K) oxazolyl, (L) pyrazinyl, (M) pyrazolyl, (N) pyridyl, (O) pyrimidyl, (P) pyrrolyl, (Q) quinolyl, (R) tetrazolyl, (S) thiadiazolyl, (T) thiazolyl, (U) thienyl, (V) triazolyl, (W) azetidinyl, (X) 1,4-dioxanyl, (Y) hexahydroazepinyl, (Z) piperazinyl, (AA) piperidinyl, (AB) pyrrolidinyl, (AC) tetrahydrofuranyl, and (AD) tetrahydrothienyl, and wherein the heterocycle is unsubstituted or substituted with one or more substituent(s) selected from: (i) C.sub.1-6 alkyl, unsubstituted or substituted with halo, --CF.sub.3, --OCH.sub.3, or phenyl, (ii) C.sub.1-6 alkoxy, (iii) oxo, (iv) hydroxy, (v) thioxo, (vi) --SR.sup.9, wherein R.sup.9 is as defined above, (vii) halo, (viii) cyano, (ix) phenyl, (x) trifluoromethyl, (xi) --(CH.sub.2).sub.m --NR.sup.9 R.sup.10, wherein m is 0, 1 or 2, and R.sup.9 and R.sup.10 are as defined above, (xii) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (xiii) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (xiv) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above, and (xv) --(CH.sub.2).sub.m --OR.sup.9, wherein m and R.sup.9 are as defined above; (3) C.sub.2-6 alkenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, (h) --CONR.sup.9 R.sup.10 wherein R.sup.9 and R.sup.10 are as defined above, (i) --COR.sup.9 wherein R.sup.9 is as defined above, (j) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above, (k) heterocycle, wherein the heterocycle is as defined above; (4) C.sub.2-6 alkynyl; (5) phenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) C.sub.1-6 alkoxy, (c) C.sub.1-6 alkyl, (d) C.sub.2-5 alkenyl, (e) halo, (f) --CN, (g) --NO.sub.2, (h) --CF.sub.3, (i) --(CH.sub.2).sub.m --NR.sup.9 R.sup.10, wherein m, R.sup.9 and R.sup.10 are as defined above, (j) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (k) --NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (l) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (m) --CO.sub.2 NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (n) --COR.sup.9, wherein R.sup.9 is as defined above; (o) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; R.sup.2 and R.sup.3 are independently selected from the group consisting of: (1) hydrogen, (2) C.sub.1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, (h) --NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (i) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (j) --NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (k) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (l) --COR.sup.9, wherein R.sup.9 is as defined above, and (m) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; (3) C.sub.2-6 alkenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, (h) --CONR.sup.9 R.sup.10 wherein R.sup.9 and R.sup.10 are as defined above, (i) --COR.sup.9 wherein R.sup.9 is as defined above, (j) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; (4) C.sub.2-6 alkynyl; (5) phenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) C.sub.1-6 alkoxy, (c) C.sub.1-6 alkyl, (d) C.sub.2-5 alkenyl, (e) halo, (f) --CN, (g) --NO.sub.2, (h) --CF.sub.3, (i) --(CH.sub.2).sub.m --NR.sup.9 R.sup.10, wherein m, R.sup.9 and R.sup.10 are as defined above, (j) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (k) --NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (l) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (m) --CO.sub.2 NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (n) --COR.sup.9, wherein R.sup.9 is as defined above; (o) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; and the groups R.sup.1 and R.sup.2 may be joined together to form a heterocyclic ring selected from the group consisting of: (a) pyrrolidinyl, (b) piperidinyl, (c) pyrrolyl, (d) pyridinyl, (e) imidazolyl, (f) oxazolyl, and (g) thiazolyl, and wherein the heterocyclic ring is unsubstituted or substituted with one or more substituent(s) selected from: (i) C.sub.1-6 alkyl, (ii) oxo, (iii) C.sub.1-6 alkoxy, (iv) --NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (v) halo, and (vi) trifluoromethyl; and the groups R.sup.2 and R.sup.3 may be joined together to form a carbocyclic ring selected from the group consisting of: (a) cyclopentyl, (b) cyclohexyl, (c) phenyl, and wherein the carbocyclic ring is unsubstituted or substituted with one or more substituents selected from: (i) C.sub.1-6 alkyl, (ii) C.sub.1-6 alkoxy, (iii) --NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (iv) halo, and (v) trifluoromethyl; and the groups R.sup.2 and R.sup.3 may be joined together to form a heterocyclic ring selected from the group consisting of: (a) pyrrolidinyl, (b) piperidinyl, (c) pyrrolyl, (d) pyridinyl, (e) imidazolyl, (f) furanyl, (g) oxazolyl, (h) thienyl, and (i) thiazolyl, and wherein the heterocyclic ring is unsubstituted or substituted with one or more substituent(s) selected from: (i) C.sub.1-6 alkyl, (ii) oxo, (iii) C.sub.1-6 alkoxy, (iv) --NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (v) halo, and (vi) trifluoromethyl; X is selected from the group consisting of: (1) --O--, (2) --S--, (3) --SO--, and (4) --SO.sub.2 --; R.sup.6, R.sup.7 and R.sup.8 are independently selected from the group consisting of: (1) hydrogen; (2) C.sub.1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, (h) --NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (i) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (j) --NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (k) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (l) --COR.sup.9, wherein R.sup.9 is as defined above, and (m) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; (3) C.sub.2-6 alkenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, (h) --CONR.sup.9 R.sup.10 wherein R.sup.9 and R.sup.10 are as defined above, (i) --COR.sup.9 wherein R.sup.9 is as defined above, (j) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; (4) C.sub.2-6 alkynyl; (5) phenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) C.sub.1-6 alkoxy, (c) C.sub.1-6 alkyl, (d) C.sub.2-5 alkenyl, (e) halo, (f) --CN, (g) --NO.sub.2, (h) --CF.sub.3, (i) --(CH.sub.2).sub.m --NR.sup.9 R.sup.10, wherein m, R.sup.9 and R.sup.10 are as defined above, (j) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (k) --NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (l) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (m) --CO.sub.2 NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (n) --COR.sup.9, wherein R.sup.9 is as defined above; (o) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; (6) halo, (7) --CN, (8) --CF.sub.3, (9) --NO.sub.2, (10) --SR.sup.14, wherein R.sup.14 is hydrogen or C.sub.1-5 alkyl, (11) --SOR.sup.14, wherein R.sup.14 is as defined above, (12) --SO.sub.2 R.sup.14, wherein R.sup.14 is as defined above, (13) NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (14) CONR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (15) NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (16) NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (17) hydroxy, (18) C.sub.1-6 alkoxy, (19) COR.sup.9, wherein R.sup.9 is as defined above, (20) CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above, (21) 2-pyridyl, (22) 3-pyridyl, (23) 4-pyridyl, (24) 5-tetrazolyl, (25) 2-oxazolyl, and (26) 2-thiazolyl; R.sup.11, R.sup.12 and R.sup.13 are independently selected from the definitions of R.sup.6, R.sup.7 and R.sup.8 ; Y is selected from the group consisting of: (1) a single bond, (2) --O--, (3) --S--, (4) --CO--, (5) --CH.sub.2 --, (6) --CHR.sup.15 --, and (7) --CR.sup.15 R.sup.16 --, wherein R.sup.15 and R.sup.16 are independently selected from the group consisting of: (a) C.sub.1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from: (i) hydroxy, (ii) oxo, (iii) C.sub.1-6 alkoxy, (iv) phenyl-C.sub.1-3 alkoxy, (v) phenyl, (vi) --CN, (vii) halo, (viii) --NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (ix) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (x) --NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (xi) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (xii) --COR.sup.9, wherein R.sup.9 is as defined above, and (xiii) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; (b) phenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (i) hydroxy, (ii) C.sub.1-6 alkoxy, (iii) C.sub.1-6 alkyl, (iv) C.sub.2-5 alkenyl, (v) halo, (vi) --CN, (vii) --NO.sub.2, (viii) --CF.sub.3, (ix) --(CH.sub.2).sub.m --NR.sup.9 R.sup.10, wherein m, R.sup.9 and R.sup.10 are as defined above, (x) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (xi) --NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (xii) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (xiii) --CO.sub.2 NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (xiv) --COR.sup.9, wherein R.sup.9 is as defined above, and (xv) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; Z is hydrogen; which comprises contacting a compound of formula V: ##STR28## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.6, R.sup.7, R.sup.8, R.sup.11, R.sup.12 and R.sup.13 are as defined above; with an inorganic or an organic acid selected from the group consisting of: toluenesulfonic acid, methanesulfonic acid, sulfuric acid, hydrochloric acid and mixtures thereof, in an aprotic solvent selected from the group consisting of: toluene, benzene, dimethylformamide, tetrahydrofuran, diethylether, dimethoxyethane, ethyl acetate, and mixtures thereof, at a temperature from 0.degree. C. to solvent reflux temperature for a sufficient time to produce a compound of structural formula IV. 21. A process for the preparation of a compound of structural formula XI: ##STR29## or a pharmaceutically acceptable salt thereof, wherein: R.sup.1 is selected from the group consisting of: (1) hydrogen; (2) C.sub.1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, (h) --NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are independently selected from: (i) hydrogen, (ii) C.sub.1-6 alkyl, (iii) hydroxy-C.sub.1-6 alkyl, and (iv) phenyl, (i) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (j) --NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (k) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (l) --COR.sup.9, wherein R.sup.9 is as defined above, (m) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; (n) heterocycle, wherein the heterocycle is selected from the group consisting of: (A) benzimidazolyl, (B) benzofuranyl, (C) benzothiophenyl, (D) benzoxazolyl, (E) furanyl, (F) imidazolyl, (G) indolyl, (H) isooxazolyl, (I) isothiazolyl, (J) oxadiazolyl, (K) oxazolyl, (L) pyrazinyl, (M) pyrazolyl, (N) pyridyl, (O) pyrimidyl, (P) pyrrolyl, (Q) quinolyl, (R) tetrazolyl, (S) thiadiazolyl, (T) thiazolyl, (U) thienyl, (V) triazolyl, (W) azetidinyl, (X) 1,4-dioxanyl, (Y) hexahydroazepinyl, (Z) piperazinyl, (AA) piperidinyl, (AB) pyrrolidinyl, (AC) tetrahydrofuranyl, and (AD) tetrahydrothienyl, and wherein the heterocycle is unsubstituted or substituted with one or more substituent(s) selected from: (i) C.sub.1-6 alkyl, unsubstituted or substituted with halo, --CF.sub.3, --OCH.sub.3, or phenyl, (ii) C.sub.1-6 alkoxy, (iii) oxo, (iv) hydroxy, (v) thioxo, (vi) --SR.sup.9, wherein R.sup.9 is as defined above, (vii) halo, (viii) cyano, (ix) phenyl, (x) trifluoromethyl, (xi) --(CH.sub.2).sub.m --NR.sup.9 R.sup.10, wherein m is 0, 1 or 2, and R.sup.9 and R.sup.10 are as defined above, (xii) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (xiii) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (xiv) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above, and (xv) --(CH.sub.2).sub.m --OR.sup.9, wherein m and R.sup.9 are as defined above; (3) C.sub.2-6 alkenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, (h) --CONR.sup.9 R.sup.10 wherein R.sup.9 and R.sup.10 are as defined above, (i) --COR.sup.9 wherein R.sup.9 is as defined above, (j) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above, (k) heterocycle, wherein the heterocycle is as defined above; (4) C.sub.2-6 alkynyl; (5) phenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) C.sub.1-6 alkoxy, (c) C.sub.1-6 alkyl, (d) C.sub.2-5 alkenyl, (e) halo, (f) --CN, (g) --NO.sub.2, (h) --CF.sub.3, (i) --(CH.sub.2).sub.m --NR.sup.9 R.sup.10, wherein m, R.sup.9 and R.sup.10 are as defined above, (j) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (k) --NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (l) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (m) --CO.sub.2 NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (n) --COR.sup.9, wherein R.sup.9 is as defined above; (o) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; R.sup.2 and R.sup.3 are independently selected from the group consisting of: (1) hydrogen, (2) C.sub.1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, (h) --NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (i) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (j) --NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (k) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (l) --COR.sup.9, wherein R.sup.9 is as defined above, and (m) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; (3) C.sub.2-6 alkenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, (h) --CONR.sup.9 R.sup.10 wherein R.sup.9 and R.sup.10 are as defined above, (i) --COR.sup.9 wherein R.sup.9 is as defined above, (j) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; (4) C.sub.2-6 alkynyl; (5) phenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) C.sub.1-6 alkoxy, (c) C.sub.1-6 alkyl, (d) C.sub.2-5 alkenyl, (e) halo, (f) --CN, (g) --NO.sub.2, (h) --CF.sub.3, (i) --(CH.sub.2).sub.m --NR.sup.9 R.sup.10, wherein m, R.sup.9 and R.sup.10 are as defined above, (j) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (k) --NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (l) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (m) --CO.sub.2 NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (n) --COR.sup.9, wherein R.sup.9 is as defined above; (o) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; and the groups R.sup.1 and R.sup.2 may be joined together to form a heterocyclic ring selected from the group consisting of: (a) pyrrolidinyl, (b) piperidinyl, (c) pyrrolyl, (d) pyridinyl, (e) imidazolyl, (f) oxazolyl, and (g) thiazolyl, and wherein the heterocyclic ring is unsubstituted or substituted with one or more substituent(s) selected from: (i) C.sub.1-6 alkyl, (ii) oxo, (iii) C.sub.1-6 alkoxy, (iv) --NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (v) halo, and (vi) trifluoromethyl; and the groups R.sup.2 and R.sup.3 may be joined together to form a carbocyclic ring selected from the group consisting of: (a) cyclopentyl, (b) cyclohexyl, (c) phenyl, and wherein the carbocyclic ring is unsubstituted or substituted with one or more substituents selected from: (i) C.sub.1-6 alkyl, (ii) C.sub.1-6 alkoxy, (iii) --NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (iv) halo, and (v) trifluoromethyl; and the groups R.sup.2 and R.sup.3 may be joined together to form a heterocyclic ring selected from the group consisting of: (a) pyrrolidinyl, (b) piperidinyl, (c) pyrrolyl, (d) pyridinyl, (e) imidazolyl, (f) furanyl, (g) oxazolyl, (h) thienyl, and (i) thiazolyl, and wherein the heterocyclic ring is unsubstituted or substituted with one or more substituent(s) selected from: (i) C.sub.1-6 alkyl, (ii) oxo, (iii) C.sub.1-6 alkoxy, (iv) --NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (v) halo, and (vi) trifluoromethyl; R.sup.6, R.sup.7 and R.sup.8 are independently selected from the group consisting of: (1) hydrogen; (2) C.sub.1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, (h) --NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (i) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (j) --NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (k) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (l) --COR.sup.9, wherein R.sup.9 is as defined above, and (m) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; (3) C.sub.2-6 alkenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, (h) --CONR.sup.9 R.sup.10 wherein R.sup.9 and R.sup.10 are as defined above, (i) --COR.sup.9 wherein R.sup.9 is as defined above, (j) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; (4) C.sub.2-6 alkynyl; (5) phenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) C.sub.1-6 alkoxy, (c) C.sub.1-6 alkyl, (d) C.sub.2-5 alkenyl, (e) halo, (f) --CN, (g) --NO.sub.2, (h) --CF.sub.3, (i) --(CH.sub.2).sub.m --NR.sup.9 R.sup.10, wherein m, R.sup.9 and R.sup.10 are as defined above, (j) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (k) --NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (l) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (m) --CO.sub.2 NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (n) --COR.sup.9, wherein R.sup.9 is as defined above; (o) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; (6) halo, (7) --CN, (8) --CF.sub.3, (9) --NO.sub.2, (10) --SR.sup.14, wherein R.sup.14 is hydrogen or C.sub.1-6 alkyl, (11) --SOR.sup.14, wherein R.sup.14 is as defined above, (12) --SO.sub.2 R.sup.14, wherein R.sup.14 is as defined above, (13) NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (14) CONR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (15) NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (16) NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above, (17) hydroxy, (18) C.sub.1-6 alkoxy, (19) COR.sup.9, wherein R.sup.9 is as defined above, (20) CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above, (21) 2-pyridyl, (22) 3-pyridyl, (23) 4-pyridyl, (24) 5-tetrazolyl, (25) 2-oxazolyl, and (26) 2-thiazolyl; R.sup.11, R.sup.12 and R.sup.13 are independently selected from the definitions of R.sup.6, R.sup.7 and R.sup.8 ; Z is hydrogen; which comprises contacting a compound of formula IX: ##STR30## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.11, R.sup.12 and R.sup.13 are defined as above; with a hydride reducing agent selected from a group consisting of: diisobutylaluminum hydride: lithium tri(sec-butyl)borohydride: and lithium aluminum hydride; in an organic solvent at low temperature; followed by acylation of the resultant alcohol/alkoxide with a substituted benzoyl halide, substituted benzoic anhydride, substituted benzoic mixed anhydride or substituted activated benzoate ester (e.g. p-nitrophenyl ester or N-hydroxysuccinimide ester), in which the phenyl ring of these acylating agents is substituted with R.sup.6, R.sup.7, and R.sup.8 as defined above, in an organic solvent at low temperature for a sufficient time to produce a compound of structural formula X: ##STR31## and subsequently contacting the compound of formula X with a titanium ylide (generated from reagents selected from: .mu.-chloro-.mu.-methylene(bis(cyclopentadienyl)titanium)dimethylamluminum ; or dimethyl titanocene; or the reagent prepared by the reduction of a 1,1-dibromoalkane with zinc and titanium tetrachloride in the presence of N,N,N',N'-tetramethylethylenediamine) to afford an enol ether which is then hydrogenated in the presence of a a catalyst selected from palladium on carbon, platinum on carbon, or rhodium on carbon to afford the compound of formula XI. |
